Literature DB >> 18926587

Serum sterols in patients with primary biliary cirrhosis and acute liver failure before and after liver transplantation.

Katriina Nikkilä1, Markku J Nissinen, Helena Gylling, Helena Isoniemi, Tatu A Miettinen.   

Abstract

BACKGROUND/AIMS: Liver diseases modify sterol metabolism. Liver transplantation (LTX) provides a model to evaluate the impact of disease-affected liver on sterol metabolism.
METHODS: We studied serum sterol profiles and their relationships to other biochemical markers in consecutive cholestatic patients with acute liver failure (ALF, n=39) and end-stage primary biliary cirrhosis (PBC, n=67) before and 27d after LTX. Accordingly, we determined serum levels of sterols, bilirubin and prealbumin.
RESULTS: Due to weak cholesterol synthesis of ALF-patients before LTX, their serum levels of cholesterol, lathosterol/cholesterol, cholestanol/cholesterol and lathosterol/campesterol were 18%-41% lower (P<0.05 for each) than in PBC, but ratios of phytosterols to cholesterol were equal. In general, non-cholesterol sterol ratios reflected bilirubin and prealbumin concentrations. Interrelation of surrogate sterols showed that homeostasis of cholesterol metabolism prevailed in lowest cholestanol tertile of ALF-patients consistently, but not in PBC. After LTX, cholesterol levels and lathosterol ratios increased in both groups and phytosterol ratios decreased (P<0.01). Cholestanol decreased profoundly in PBC, but remained 26% higher than in ALF (P<0.05).
CONCLUSIONS: Homeostasis of cholesterol metabolism was maintained only in ALF. Metabolism of phytosterols was equal in study groups. PBC- and ALF-patients have differential patterns in their serum sterols and cholesterol metabolism.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18926587     DOI: 10.1016/j.jhep.2008.07.026

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  7 in total

1.  Plasma noncholesterol sterols as indicators of cholesterol absorption.

Authors:  Scott M Grundy
Journal:  J Lipid Res       Date:  2013-02-12       Impact factor: 5.922

Review 2.  Cholesterol metabolism in cholestatic liver disease and liver transplantation: From molecular mechanisms to clinical implications.

Authors:  Katriina Nemes; Fredrik Åberg; Helena Gylling; Helena Isoniemi
Journal:  World J Hepatol       Date:  2016-08-08

3.  Circulating Lipids Are Associated with Alcoholic Liver Cirrhosis and Represent Potential Biomarkers for Risk Assessment.

Authors:  Peter J Meikle; Piyushkumar A Mundra; Gerard Wong; Khairunnessa Rahman; Kevin Huynh; Christopher K Barlow; Alastair M P Duly; Paul S Haber; John B Whitfield; Devanshi Seth
Journal:  PLoS One       Date:  2015-06-24       Impact factor: 3.240

4.  Circulating sterols as predictors of early allograft dysfunction and clinical outcome in patients undergoing liver transplantation.

Authors:  Uta Ceglarek; Kathleen Kresse; Susen Becker; Georg Martin Fiedler; Joachim Thiery; Markus Quante; Robert Wieland; Michael Bartels; Gabriela Aust
Journal:  Metabolomics       Date:  2016-10-24       Impact factor: 4.290

Review 5.  The Interpretation of Cholesterol Balance Derived Synthesis Data and Surrogate Noncholesterol Plasma Markers for Cholesterol Synthesis under Lipid Lowering Therapies.

Authors:  Frans Stellaard; Dieter Lütjohann
Journal:  Cholesterol       Date:  2017-02-22

6.  A novel fibrosis index comprising a non-cholesterol sterol accurately predicts HCV-related liver cirrhosis.

Authors:  Magdalena Ydreborg; Vera Lisovskaja; Martin Lagging; Peer Brehm Christensen; Nina Langeland; Mads Rauning Buhl; Court Pedersen; Kristine Mørch; Rune Wejstål; Gunnar Norkrans; Magnus Lindh; Martti Färkkilä; Johan Westin
Journal:  PLoS One       Date:  2014-04-03       Impact factor: 3.240

7.  Age-related changes of cholestanol and lathosterol plasma concentrations: an explorative study.

Authors:  Monica Gelzo; Maria Donata Di Taranto; Concetta Sica; Antonio Boscia; Francesco Papagni; Giuliana Fortunato; Gaetano Corso; Antonio Dello Russo
Journal:  Lipids Health Dis       Date:  2019-12-30       Impact factor: 3.876

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.